Bell & Brown Wealth Advisors’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Bell & Brown Wealth Advisors’s Portfolio STAB Stock Details STAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-17,000	Closed	-$1.38K	–	72
2022 Q4	$1.38K	Sell	17,000 -1,313	-7%	-$167	﹤0.01%	71
2022 Q3	$2K	Hold	18,313	–	–	﹤0.01%	64
2022 Q2	$5K	Sell	18,313 -1,000	-5%	-$259	﹤0.01%	73
2022 Q1	$6K	Hold	19,313	–	–	﹤0.01%	75
2021 Q4	$19K	Buy	+19,313	New	+$57K	0.01%	69

Other funds holding STAB

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TAM

Tucker Asset Management Littleton, Colorado $343M AUM 17.55% 1-Year Est. Return

Bell & Brown Wealth Advisors's STAB Position: Q1 2023 in Review

Bell & Brown Wealth Advisors sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q1 2023, closing a stake of 17,000 shares — an estimated $1.38K sold.

Bell & Brown Wealth Advisors first reported a position in STAB in Q4 2021 and held it in 5 quarters. The position peaked at $19K in Q4 2021. 4 funds tracked by Wall St. Rank hold STAB as of Q1 2023.

Bell & Brown Wealth Advisors reported no remaining Statera Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Bell & Brown Wealth Advisors sold 17,000 Statera Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $1.38K.
Bell & Brown Wealth Advisors first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
Bell & Brown Wealth Advisors's Statera Biopharma, Inc. Common Stock position peaked at $19K in Q4 2021.
4 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q1 2023.

Based on Bell & Brown Wealth Advisors's 13F filing for Q1 2023, filed 14 Apr 2023.